Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia - PubMed (original) (raw)

. 1997 Feb 1;57(3):396-9.

Affiliations

PMID: 9012463

Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia

N Bertin et al. Cancer Res. 1997.

Abstract

Thrombospondin-1 (TSP1) is a Mr 450,000 extracellular matrix glycoprotein that modulates tumor growth, angiogenesis, and metastasis. Of the five structurally different TSPs described to date, only TSP2 is similar to TSP1 in terms of its molecular architecture, and TSP2 also modulates angiogenesis. Angiogenesis plays a relevant role in the biological aggressiveness of breast cancer, and TSP1 is present in the tumor stroma (termed desmoplasia) of invasive human breast ductal carcinoma not otherwise specified (NOS). The present study was designed to identify and quantify TSP1 and TSP2 mRNAs in normal, benign, and neoplastic human breast tissues using the reverse transcriptase PCR technique. We found that TSP2, like TSP1, was expressed in human breast tissues, and that TSP1 and TSP2 mRNA expression in invasive breast carcinoma NOS was significantly increased compared to that observed in normal and benign tissues. The expression of TSP1 and TSP2 in invasive breast ductal carcinoma NOS did not significantly correlate with any of the prognostic factors studied (tumor size, lymph node status, morphology, and hormone receptor status). However, when our study population was divided according to the quantity of tumor stroma, TSP1 (and possibly TSP2) mRNA expression and microvessel counts in desmoplastic-rich stroma of breast carcinoma NOS were significantly increased compared to those observed in desmoplastic-poor stromata.

PubMed Disclaimer

Cited by

Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis.
Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M. Streit M, et al. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14888-93. doi: 10.1073/pnas.96.26.14888. Proc Natl Acad Sci U S A. 1999. PMID: 10611308 Free PMC article.
Immunohistochemical study of thrombospondin and its receptors alpha root of beta 3 and CD36 in normal thyroid and in thyroid tumours.
Patey M, Delemer B, Bellon G, Martiny L, Pluot M, Haye B. Patey M, et al. J Clin Pathol. 1999 Dec;52(12):895-900. doi: 10.1136/jcp.52.12.895. J Clin Pathol. 1999. PMID: 10711252 Free PMC article.
In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.
Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F. Filleur S, et al. Genes Dev. 2001 Jun 1;15(11):1373-82. doi: 10.1101/gad.193501. Genes Dev. 2001. PMID: 11390357 Free PMC article.
Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.
Lawler J. Lawler J. J Cell Mol Med. 2002 Jan-Mar;6(1):1-12. doi: 10.1111/j.1582-4934.2002.tb00307.x. J Cell Mol Med. 2002. PMID: 12003665 Free PMC article. Review.
Estrogen regulation of thrombospondin-1 in human breast cancer cells.
Hyder SM, Liang Y, Wu J. Hyder SM, et al. Int J Cancer. 2009 Sep 1;125(5):1045-53. doi: 10.1002/ijc.24373. Int J Cancer. 2009. PMID: 19391135 Free PMC article.

Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia - PubMed (original) (raw)